Waning efficacy in a long-term AAV-mediated gene therapy study in the murine model of Krabbe disease
Journal
Molecular therapy
Publication Date
5-5-2021
Volume
29
Issue
5
First Page
1883
Last Page
1902
Document Type
Open Access Publication
DOI
10.1016/j.ymthe.2021.01.026
Rights and Permissions
Heller GJ, Marshall MS, Issa Y, Marshall JN, Nguyen D, Rue E, Pathmasiri KC, Domowicz MS, van Breemen RB, Tai LM, Cologna SM, Crocker SJ, Givogri MI, Sands MS, Bongarzone ER. Waning efficacy in a long-term AAV-mediated gene therapy study in the murine model of Krabbe disease. Mol Ther. 2021 May 5;29(5):1883-1902. doi: 10.1016/j.ymthe.2021.01.026. Copyright 2021 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Recommended Citation
Heller, Gregory J; Marshall, Michael S; Issa, Yazan; Marshall, Jeffrey N; Nguyen, Duc; Rue, Emily; Pathmasiri, Koralege C; Domowicz, Miriam S; van Breemen, Richard B; Tai, Leon M; Cologna, Stephanie M; Crocker, Stephen J; Givogri, Maria I; Sands, Mark S; and Bongarzone, Ernesto R, "Waning efficacy in a long-term AAV-mediated gene therapy study in the murine model of Krabbe disease." Molecular therapy. 29, 5. 1883 - 1902. (2021).
https://digitalcommons.wustl.edu/open_access_pubs/10797